Azafaros B.V.
June 16, 2025
Company Presentation
Brain Health
Azafaros, founded in 2018, is a clinical-stage company addressing lysosomal storage disorders, including GM1 and GM2 gangliosidoses and Niemann-Pick type C. With roots in discoveries from Leiden University and Amsterdam UMC, and led by a team of industry veterans, Azafaros is committed to delivering disease-modifying therapies for rare genetic diseases. Poised to start a global Phase III clinical trial for its lead asset, Azafaros is achieving a key milestone in its mission to bring innovative treatments to patients and families affected by devastating disorders. By leveraging its scientific expertise, extensive network, and innovative mindset, the company challenges conventional pathways to accelerate the development of life-changing therapies. Backed by leading investors such as Forbion, BioGeneration Ventures, BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital, Azafaros is uniquely positioned to make a significant impact on rare disease treatment worldwide.
Company HQ City:
DC Naarden
Company HQ Country:
Netherlands
Year Founded:
2018
Lead Product in Development:
Nizubaglustat
CEO
Stefano Portolano
Year Founded
2018
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
$100M+ Series B near closing, with plans to initiate two Phase III trials across three indications.
What is your next catalyst (value inflection) update?
Mid Q2 2025
Website
https://www.azafaros.com/about-us
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}